Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

Seidman, Andrew D.; Reichman, Bonnie; Crown, John; Yao, Tzy‐Jyun; Currie, Violante E.; Hakes, T.; Hudis, Clifford A.; Gilewski, Theresa; Baselga, José; Forsythe, Paul

doi:10.1200/jco.1995.13.5.1152

Cited by 189 publications

(57 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median duration of response (7.6 months), time to progression (4.8 months) and estimated survival (13.0 months) are not very different from the results reported with chemotherapy alone [19]. Similar results have also been reported by other investigators applying the same agents in a salvage regimen with some differences in regards to the intervals of paclitaxel administration (biweekly) and patient's characteristics since one third of them were HER2 positive [25].…”

Section: Discussionsupporting

confidence: 76%

“…Paclitaxel (P) has demonstrated single agent response rates of 35% to 53% even as second or third-line treatment [19]. In addition, bevacizumab (B) combined with several chemotherapeutic agents has shown a synergistic effect that was translated into an increase of the response rate in pretreated patients [10] and an increase of the response rate and progression free survival (PFS) as first-line treatment [11] in MBC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

Polyzos

Kalbakis

Kentepozidis

et al. 2010

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

Polyzos

Kalbakis

Kentepozidis

et al. 2010

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…This alternative schedule of administration is supported by an interesting preclinical rationale (Norton, 1997); in addition, the sequence of Epirubicin followed by Paclitaxel (3-h infusion) is also supported by clinical data showing the partially non crossresistance of the two drugs (Gianni et al, 1995a;Seidman et al, 1995). Our group carried out a multicenter randomised phase III trial testing the safety, activity and efficacy of two different schedules of Epirubicin and Paclitaxel (concurrent vs sequential) in advanced breast cancer patients.…”

mentioning

confidence: 98%

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

et al. 2004

View full text Add to dashboard Cite

The aim of the study was to evaluate cardiac safety of two different schedules of Epirubicin and Paclitaxel in advanced breast cancer patients enrolled into a multicenter randomized phase III trial. Patients received Epirubicin 90 mg m À2 plus Paclitaxel 200 mg m À2 (3-h infusion) on day 1 every 3 weeks for eight courses (arm A), or Epirubicin 120 mg m À2 on day 1 every 3 weeks for four courses followed by four courses of Paclitaxel 250 mg m À2 on day 1 every 3 weeks (arm B). Left ventricular ejection fraction was evaluated by bidimesional echocardiography at baseline, after four and eight courses of chemotherapy and every 4 months during follow-up. Baseline median left ventricular ejection fraction was 60% in arm A and 65% in arm B; after four courses, figures were 57 and 60%, respectively. After eight courses, the median left ventricular ejection fraction in arm A declined to 50% while no further reduction was detected in arm B by adding four courses of high-dose Paclitaxel. Seven episodes of congestive heart failure were observed during treatment in arm A. Present monitoring demonstrated that the risk of congestive heart failure or impairment in the cardiac function correlated only with the cumulative dose of Epirubicin; no impact on cardiotoxicity can be attributed to high-dose Paclitaxel.

show abstract

“…Paclitaxel is highly effective for both breast cancer without previous treatment (7) and breast cancer previously treated with anthracycline (8). Findings in a Japanese late phase II study showed the effective rate in metastatic breast cancer patients to be 33.7% (21/62) (9).…”

Section: Introductionmentioning

confidence: 99%

Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil

Osaki

Mitsuyama²,

Kurebayashi³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. the study present the results of the dose-setting study of concomitant weekly administration of paclitaxel and tegafur·uracil (UFt) for metastatic breast cancer. eligible patients who entered the study underwent two or more courses of weekly paclitaxel + UFt therapy as the protocol therapy. the initial dose (level 1) was paclitaxel, 80 mg/m 2 and UFt, 400 mg/day. At level 2, paclitaxel remained the same, but UFt was increased to 600 mg/day. At level 3, only paclitaxel was increased to 90 mg/m 2 . twelve patients were enrolled in this study between september 2000 and september 2002. three patients were assigned to level 1. grade 3 liver dysfunction (increased aspartate aminotransferase and alanine aminotransferase) was noted in one patient and grade 4 neutropenia was noted in one patient, showing that dose-limiting toxicity was detected in 2/3 patients. In accordance with the protocol, UFT was fixed at 400 mg/day and paclitaxel was decreased to 60 mg/m 2 at level -1, and then increased to 70 mg/m 2 at level 0. the overall effective rate after completion of two courses was 33% (3/9) including one case of complete response and two cases of partial responses. the remaining patients presented with stable diseases and no patient had progressive disease. In this study, weekly paclitaxel with concomitant UFt was administered. the recommended doses of paclitaxel and UFt were determined to be 70 mg/m 2 and 400 mg/day, respectively. As the toxicity profile shows, the highest toxicity level of this regimen was neutropenia and liver dysfunction, and doselimiting toxicity was neutropenia. IntroductionAn anthracycline-containing regimen represents the first-line palliative chemotherapy (1-3). However, it is necessary to develop non-anthracycline combination regimens to provide salvage therapy in metastatic breast cancer patients who have relapsed during or after anthracycline-containing combinations. Although new salvage chemotherapy using (or in combination with) novel anticancer drugs has been studied (4-6), survival benefits and higher response rates are often countered by increased toxicity and complexity of regimen. An effective combination chemotherapy regimen that is both simple and has lesser toxicity would be valuable.Paclitaxel is highly effective for both breast cancer without previous treatment (7) and breast cancer previously treated with anthracycline (8). Findings in a Japanese late phase II study showed the effective rate in metastatic breast cancer patients to be 33.7% (21/62) (9). clinical evaluation of weekly regimens was frequently performed. Higher effects with mild adverse events compared to those of the approved dosage/application method, comprising an every-three-week regimen, have also been reported (10). these regimens can be administered on an outpatient basis, which is an advantage.5-Fluorouracil is used in combination with anthracycline anticancer drugs and cyclophosphamide for the treatment of breast cancer and is administered by bolus injection in many cases. However, continuous intrave...

show abstract

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

Cited by 189 publications

References 16 publications

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil

Contact Info

Product

Resources

About